Getting the right answers matters to make reliable clinical decisions.
NOVEOS™ the new standard to LIMIT the impact of INTERFERENCES!
Avoiding False Negatives
The NOVEOS indirect assay design avoids competition for binding sites by patient allergen-specific antibodies and endogenous biotin in a patient sample.
Positive results by a single method, negative by all others
Avoiding False Positives
The assay design of NOVEOS is unaffected by biotin or cellulose-based CCD interference. The small sample volume per test leads to less interference from serum-based substances. The microparticle approach gives a dramatic increase in surface area leading to superb sensitivity.